PBLS peer analysis
Parabilis Medicines (PBLS) against its competitors: price, today's move, 1-year return and market value side by side.
PBLS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| CBIO Crescent Biopharma | $13.85 | 1.47% | 5.48% | $514.44M |
| CGEM Cullinan Therapeutics | $11.20 | -4.52% | 55.77% | $688.33M |
| CTMX CytomX Therapeutics | $2.00 | 0.76% | -44.89% | $434.71M |
| FHTX Foghorn Therapeutics | $1.90 | -6.86% | -56.42% | $112.83M |
| GLUE Monte Rosa Therapeutics | $10.49 | -0.85% | -14.78% | $894.94M |
| IMNM Immunome | $18.65 | -3.67% | 22.38% | $2.20B |
| MGNX MacroGenics | $2.42 | 3.21% | 76.28% | $153.84M |
| RLAY Relay Therapeutics | $19.93 | -2.26% | 229.42% | $4.37B |
| TNGX Tango Therapeutics | $24.29 | 6.82% | 208.64% | $4.10B |
| ZYME Zymeworks | $31.45 | 2.08% | 91.07% | $2.26B |
| PBLS Parabilis Medicines | $30.02 | -1.15% | – | $3.66B |
- PBLS's peers: CBIO (Crescent Biopharma), CGEM (Cullinan Therapeutics), CTMX (CytomX Therapeutics), FHTX (Foghorn Therapeutics), GLUE (Monte Rosa Therapeutics), IMNM (Immunome), MGNX (MacroGenics), RLAY (Relay Therapeutics).
Updated 2026-11-11 00:47 UTC